Herbal formula Xinshuitong capsule exerts its cardioprotective effects via mitochondria in the hypoxia-reoxygenated human cardiomyocytes

Chunjiang Tan*, Jianwei Zeng, Yanbin Wu, Jiahui Zhang and Wenlie Chen†

Abstract

Background: The collapse of mitochondrial membrane potential (ΔΨm) resulted in the cell apoptosis and heart failure. Xinshuitong Capsule (XST) could ameliorate left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) classes and the quality of life in patients with chronic heart failure in our clinical study, however, its cardioprotective mechanisms remain unclear.

Methods: Primary human cardiomyocytes were subjected to hypoxia-reoxygenation and treated with XST 200, 400 and 600 μg/ml. The model group was free of XST and the control group was cultured in normal conditions. Cell viability, ΔΨm, the activity of mitochondrial respiratory chain complexes, ATPase activity, reactive oxygen species (ROS) and apoptosis cells were determined in all the groups.

Results: The cell viability in the XST-treated groups was significantly higher than that in the model group (P < 0.05). Coupled with the restoration of the ΔΨm, the number of polarized cells increased dose dependently in the XST-treated groups. XST also restored the lost activities of mitochondrial respiratory chain complexes I-IV induced by the oxidative stress. The total of mitochondrial ATPase activity was significantly elevated at XST 400 and 600 μg/ml compared to the model group (P < 0.05). The levels of mitochondrial ROS and the number of apoptosis cells declined in the XST-treated groups compared to those in the model group (P < 0.05).

Conclusions: XST, via restoration of ΔΨm and the mitochondrial respiratory chain complexes I-IV activities, and suppression of mitochondrial ROS generation and the apoptosis cells, maintained the integrity of the mitochondrial membrane to exert its cardioprotective effects in the hypoxia-reoxygenated human cardiomyocytes.

Keywords: Xinshuitong capsule, Mitochondrial potential, Hypoxia-reoxygenated human cardiomyocytes

Background

Mitochondria, as the power house of the heart, are highly packed in the cardiomyocytes. Cardiac cells under prolonged hypoxia condition have been shown with the opening of mitochondrial permeability transition pore (MPTP) [1]. Due to the opening of MPTP causes a transient hyperpolarization, followed by depolarization, and subsequently the collapse of the mitochondrial membrane potential (ΔΨm), which is characterized by mitochondrial swelling and uncoupling. Thus, MPTP opening and mitochondrial ΔΨm collapse have been regarded as a primary mediator of apoptosis in the ischemia-reperfusion heart injury [2, 3].

The mitochondrial electron transport chain (ETC) is found in the inner membrane, where it serves as the site of oxidative phosphorylation through the use of ATP synthase. During this chemical process, ROS can be formed as a byproduct of normal cellular aerobic metabolism in the heart [4, 5]. Thus, the major process from which the heart derives sufficient energy can also result in the production of ROS [5]. On the other hand, ROS can depress the activity of mitochondrial ETC and alter...
ion pump function in heart [6]. Mounting evidence has strongly implicated ROS signaling in the genesis of cardiac hypertrophy [7–9]. Therefore, maintaining the integrity of the mitochondrial membrane, enhancing antioxidant defense may be a therapeutic method for the protection of cardiomyocytes against the injury of ischemia or hypoxia.

Xinshuitong Capsule (XST, awarded the Invention Patent of the People’s Republic of China, No.ZL201210197892.X), a Chinese herbal medicine formula for chronic heart failure (CHF), which consists of Astragali radix, Pseudostellariae radix and Salviae miltiorrhizae radix et al., has the effects of benefiting Qi and Yang, activating blood and eliminating stasis, and inducing diuresis to alleviate edema. Our previous clinical study showed that the CHF patients, who received XST treatment (3 capsules, tid.), were significantly ameliorated in left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) classes, the symptoms and the quality of life compared to the control group [10]. In vitro, XST-treated hypoxia-reoxygenated human cardiomyocytes showed more tolerant to hypoxia stress. The cells exhibited more regular shape and size than the control [11]. However, the drug’s cardioprotective mechanisms remain elusive, especially, its actions on MPTP and mitochondrial apoptosis pathway. Thus, in current experiments, mitochondrial ΔΨm and mitochondrial mass, the activities of the mitochondrial ETC and the mitochondrial ATPase, and their associations with ROS levels and apoptosis cells will be studied in the hypoxia-reoxygenated cardiomyocytes.

Methods

Hypoxia-reoxygenated cell model

Primary human cardiomyocyte (HCM) was purchased from American Science Cell Research Laboratories (San Diego, USA). When the cells reached 80–90% confluence, they were placed on a 96-well plate or a petri dish at a density of 0.75 × 105 cells/ml in a hypoxia chamber (80%N2, 10%H2, 10%CO2 and 0.2%O2) for 12 h, followed by 2 h reoxygenation. During the process of hypoxia and reoxygenation, the study group were exposed to the water-extract of XST (200, 400 and 600 μg/ml, respectively), while the model group was cultured in normal conditions. The drug administratively), while the model group was cultured in the identical conditions of the mitochondrial membrane, where it can form aggregates due to the state of the mitochondrial ΔΨm. This aggregation changes the fluorescence properties of JC-1 from green to orange fluorescence as the ΔΨm increased. After treatment, cells were harvested, re-suspended and incubated with 10 μg/ml JC-1 at 37 °C for 30 min as before [13, 14]. The cells were then washed and centrifuged, the intact living cells stained the mitochondria with JC-1 would exhibit a pronounced orange fluorescence, however, the cells with a breakdown of ΔΨm showed a decrease of the orange fluorescence (or an increase of the green fluorescence). Thus, the intact and injured cells could be distinguished, and the cell populations were counted according to the different fluorescence by the flow cytometry (BD Biosciences, CA). (JC-1 green: Ex/Em = 485/525 nm; JC-1 red: Ex/Em = 535/590 nm).

Similarly, the fluorescence intensity of JC-1 as the index of ΔΨm alterations could be detected by a confocal microscope (Carl Zeiss AG, Oberkochen, Germany), and the ratio of red/green fluorescence intensity is indicated as the alterations of mitochondrial ΔΨm.

For quantification of mitochondrial mass, we used Mitotracker Green probe (Molecular Probes), which preferentially accumulates in mitochondria regardless of the mitochondrial membrane potential and provides an accurate assessment of mitochondrial mass. Firstly, the cells were washed with PBS and incubated at 37 °C for 30 min with 100 nM MitoTracker Green FM (Molecular Probes) and then harvested using trypsin/EDTA and re-suspended in PBS. Fluorescence intensity was detected with excitation and emission wavelengths of 490 and 516 nm, respectively, and values were corrected for total protein (mg/ml).

Determination of the activities of mitochondrial respiratory chain complexes

According to manufacturer’s instructions, mitochondrial isolation was performed at 4 °C using a Kit for cultured mammal cell (Thermo Scientific Rockford, USA).

The activities of mitochondrial respiratory chain complexes were analyzed by spectrophotometer (Secomam, Domont, France) as described before [13]. Briefly, complex I (NADH dehydrogenase, EC 1.6.5.3) enzyme activity was measured as a decline in absorbance from NADH oxidation by decylubiquinone before and after adding rotenone (St. Louis, MO, USA). Complex II (succinate dehydrogenase, EC 1.3.5.1) activity was
determined as a function of the decrease in absorbance from 2, 6-dichloroindophenol reduction. Complex III (ubiquinone cytochrome c oxidoreductase, EC 1.10.2.2) activity was calculated as a function of increase in absorbance from cytochrome c reduction. And complex IV (cytochrome c oxidoreductase, EC 1.9.3.1) activity was measured as a function of the decrease in absorbance from cytochrome c oxidation. Mitochondrial complexes activities were normalized to whole mitochondrial protein content and expressed as arbitrary units.

**Determination of mitochondrial total ATPase activity**

Cell mitochondria and submitochondrial particles were prepared as described before [14]. Briefly, the mitochondrial particles were incubated at 37 °C for 60 min in a 0.5 ml medium containing 2 mmol/l ATP, 100 mmol/l NaCl, 20 mmol/l KCl, 5 mmol/l MgCl₂, 1 mmol/l EDTA in 50 mmol/l Tris–HCl (pH = 7.0). The tubes were chilled immediately and centrifuged at 200×g for 10 min. Inorganic phosphate liberated in the supernatant was calculated as an indication of ATPase activity according to Fiske and Subbarow [15]. Protein determination was carried out in accordance with Lowry [16] with crystalline bovine serum albumin as a standard.

**Determination of mitochondrial ROS**

As described before [13], mitochondrial ROS production was determined using Amplex Red (Molecular Probes, Eugene, OR, USA). Briefly, superoxide dismutase (SOD) was added at 40 units/ml to convert all superoxide into H₂O₂. Resorufin formation (Amplex Red oxidation by H₂O₂) was detected at an excitation/emission wavelength of 545/590 nm using a spectrophotometer (Secomam, Domont, France). Readings of resorufin formation were recorded every 5 min for 30 min, and a slope (i.e., rate of formation) was produced. The slope obtained was converted into the rate of H₂O₂ production with a standard curve. The assay was done at 37 °C in 96-well plates using succinate. The data was converted to nmol/mg protein/minute.

**Quantitative assessment of apoptosis cells by flow cytometry**

As described before [17], Annexin V-APC/7-AAD Apoptosis Detection Kits (Becton-Dickinson Biosciences) were used to detect apoptosis cells. The cells stained with annexinV+/7-AAD- were considered apoptosis cells, and the percentage of apoptosis cells was determined by flow cytometry.

**Statistical analysis**

Software of SPSS Version 19.0 was used for statistical analysis. Numerical data are expressed as means ± SD. The significance of differences was examined using the ANOVA method. Results with $P<0.05$ were considered to be significant.

**Results**

XST increased the viability of hypoxia-reoxygenated HCM

As shown in Fig. 1, the cell viability in the XST-treated 200, 400 and 600 μg/ml group were 77, 81 and 84%, respectively. No difference was found between the XST-treated groups or the XST-treated groups compared to the control group. All samples were checked in three independent experiments with three replicates each. Data are represented as the mean ± SD ($P<0.05$ vs. each of the three XST-treated groups or the control group).
respectively, which showed a significant difference than the model group (42.20%, $P < 0.05$). However, the cell viability exhibited no difference between the three dosages of XST ($P > 0.05$). Under the light microscope, cells in the three XST-treated groups and the control group grew similarly well, and the cells were like in size and shape. By contrast, most of the cells in the model group showed swelling and was out of the regular shape and size (figures not shown). The data indicated that XST could protect the cells against hypoxia-induced injury.

**XST dose-dependently increased the number of polarized cells**

JC-1 is capable of entering selectively into mitochondria, and the color of the dye changes reversibly from green to orange as the mitochondrial membrane becomes more polarized. Based upon the specific fluorescent characteristics, the cells could be classified into two groups of cells by the flow cytometer, and the two kinds of fluorescence were indicated as the two populations of cells. Quantitative assessment was reflected by the dot plots as indicated in Fig. 2. The ratio of red/green fluorescence, as

![Fig. 2](image)

*Fig. 2* The cell suspensions were analyzed and sorted with flow cytometry according to the different intensity of red and green fluorescence in the five groups. X and Y axes indicated the logarithm of the relative intensity of green and red fluorescence, respectively. Bar graphs. a showed the quantitative assessment of the red/green fluorescence intensity ratio. All samples were checked in three independent experiments with three replicates each. Data are represented as the mean ± SD (**$P < 0.001$** vs. control group).
the index of cell populations, showed a dose-dependent increase in the three XST-treated groups. A significant difference was noted at XST400 and XST600μg/ml compared to the model group (P < 0.05), suggesting that XST could increase the polarized cell populations (Fig. 2a).

**XST dose dependently restored the loss of ΔΨm and mitochondrial mass induced by hypoxia**

The intensity of red fluorescence of JC-1 aggregates detected by confocal laser scanning microscopy decreased in the model group, however, XST could dose dependently increase the fluorescence, indicating that the drug could restore the loss of ΔΨm induced by hypoxia as showed in Fig. 3. Further, the red/green fluorescence ratio in XST-treated 200, 400 and 600μg/ml groups was 55, 81 and 85%, respectively, a significant difference was found in the XST-treated groups compared to the model group (18%). However, no difference was found between XST400, XST600μg/ml and the control (P > 0.05) as indicated by the bar graph Fig. 3a.

Further, an accurate assessment of mitochondrial mass was conducted, showing the green fluorescence increased in the XST-treated groups (Fig. 4). A significant elevation was noted in XST-400 and 600μg/ml groups compared to that in the model group, suggesting the drug prevented the loss of mitochondria in the hypoxia cells. The data was in line with the status of mitochondrial ΔΨm detected in above experiments. Additionally, morphological observations showed the cells in the XST-treated groups were more uniform in shape and size compared to those in the model group.

**XST restored the mitochondrial electron transport chain complexes activities**

The activities of mitochondria complexes I, II, III, and IV were assessed by spectrophotometric methods. As showed in Fig. 5, the activities of complexes I-IV were reduced in varying degrees in the model group. XST could dose dependently restore the activities of complexes I, II and III, but the activity of complex IV showed no difference among XST 200, 400 and 600 μg/ml groups. Complexes I-IV activities were significantly elevated in XST 200 and 400 μg/ml groups than those in the model group (P < 0.05); in the XST 600 μg/ml group, the activities of complexes I-IV restored nearly to the normal levels. The data indicated that the drug could dose dependently restore the activities of the mitochondrial electron transport chain complexes I-IV.

**XST increased mitochondrial total ATPase activity in the hypoxia-reoxygenated HCM**

Mitochondrial total ATPase activity was determined by estimating the amount of ATP hydrolyzed in terms of inorganic phosphorus (Pi) liberated in the cell supernatant. As shown in Fig. 6, the ATPase activity in the model group decreased about 70% compared to the control (P < 0.05), however, the activity increased about 40, 52 and 60% in the XST-treated 200, 400 and 600 μg/ml groups compared to
the model group \((P < 0.05)\), which indicated that XST dose dependently increased the mitochondrial ATPase activity induced by hypoxia. The XST-induced elevation of ATPase activity was correlated with the increase in mitochondrial \(\Delta\psi_m\) and the activities of mitochondrial complexes I-IV in the XST-treated groups (Figs. 3 and 5).

XST decreased mitochondrial ROS production in the hypoxia-reoxygenated HCM

As shown in Fig. 7, the mitochondrial ROS in the model group was about three times higher than that in the control group \((P < 0.05)\), however, all the three XST-treated groups exhibited a significant decrease in ROS levels compared to the model group \((P < 0.05)\), no difference was noted between the three dosages of XST-treated groups \((P > 0.05)\). Previous studies reported that the increase in mitochondrial \(\Delta\psi_m\) and ATPase activity led to the decrease in mitochondrial ROS production [18]. Here, we confirmed that the XST-induced increase in \(\Delta\psi_m\) and ATPase activity was coupled with a decrease in ROS. The data suggested that the three dosages of XST had the similar inhibitory effects on the production of mitochondrial ROS in hypoxia-reoxygenated HCM.

XST decreased the apoptosis cells in the hypoxia-reoxygenated HCM

As detected by flow cytometry, apoptosis cells, which stained with annexinV+/7-AAD–, were significantly increased in the model group than those in the control group \((P < 0.05)\) (Fig. 8). XST treatment could significantly decrease the apoptosis cells; however, no
difference was noted between the three XST-treated groups ($P > 0.05$). The quantitative assessment of the apoptosis cells was indicated by bar graphs Fig. 8a.

**Discussion**

Mitochondria, as the dominant source of heart ATP, represent approximately one-third of the mass of the heart and play a critical role in maintaining cellular function. The mitochondrion is very susceptible to damage mediated by ischemia or ischemia/reperfusion. The damaged mitochondria cause a depletion in ATP and a release of cytochrome c, which leads to activation of caspases and onset of apoptosis [19–21]. As such, maintaining mitochondrial homeostasis is critical to cell survival.

Current experiments showed that XST could maintain the activities of mitochondrial electron transport chain...
complexes I-IV, and restore the mitochondrial Δψm and mitochondria mass induced by oxidative stress in the cardiomyocytes. Further, the drug could activate mitochondrial total ATPase to supply cells energy to raise the cell viability in the anoxic conditions. On the other hand, XST could suppress the mitochondrial ROS generation and attenuate the ROS-induced damage to the cells, which may partly account for this drug's inhibition of apoptosis and the increase in cell viability. The current data suggested that XST exerted its cardioprotective effects via maintaining the integrity of mitochondria in the hypoxia-reoxygenated HCM.

Our previous clinical study showed that the CHF patients treated with XST (0.3 g each capsule, three capsules each time, tid.) showed significant improvement in LVEF, NYHA classes, as well as the symptoms (dyspnea, edema and etc.) and the patients' quality of life [22]. Further, in vitro experiments verified that dosages 200-600 μg/ml had the optimal cell protective effects in the oxidative stress conditions [11]. Based on the previous data, we used these dosages in the current study, which confirmed that XST could restore the Δψm and mitochondria mass to elevate the polarized cell populations. Treated at XST600μg/ml, the activities of respiratory chain complexes I-IV regained their activities nearly to the normal levels, and the total of mitochondrial ATPase activity was raised by XST. On the other hand, XST suppressed the generation of mitochondrial ROS and cell apoptosis. The data may partly shed a light on the drug's therapeutic effects on the CHF patients.

Previous studies showed that an elevated Δψm was associated with the enhanced mitochondrial ROS formation [18, 23], and a slight decrease in Δψm could prevent ROS formation without seriously compromising cellular energetics [18, 24, 25]. However, in the isolated energized cardiac mitochondria, which were induced by hypoxia, caused the inhibition of the activity of the electron transport chain, and this mild decrease in Δψm led to ROS formation during reoxygenation [26]. The collapse of mitochondrial Δψm, regarded as an index of mitochondrial inner integrity, would go hand in hand with the dysfunctions of the mitochondrial respiratory chain and a decline of ATPase activity, which led to the elevation of mitochondrial ROS formation and cell apoptosis. The phenomena were supported in the current experiments as showed in Figs. 3, 5 and 7. XST treatment could restore the loss of Δψm and repaired the dysfunctions of the mitochondrial respiratory chain. Additionally, XST could activate ATPase and suppress ROS formation, resulted in the decline in apoptosis cells in the hypoxia-reoxygenated HCM. These data suggested that XST possibly exerted its cardioprotective effects partly through mitochondria. Mitochondrial respiratory chain, especially, complex I, III and III, were seen as the prime source of ROS [27–30]. ROS generations are decreased when the available electrons are limited and potential energy for the transfer is low [30].
Recent study found that when the electron transport chain functions of complexes I, III and III are at the suboptimal level, the rate of mitochondrial free radical production is inversely increasing proportional to the rate of electron transport [31], suggesting that the elevated ROS levels found under these conditions may originate extra-mitochondrially or are attributed to the defective antioxidant defense. Our experiments showed that XST-induced elevation of mitochondrial respiratory chain complexes activities was inversely correlated with the levels of mitochondria-derived ROS in the XST-treated groups (Figs. 5 and 7). Possibly, the drug chain complexes activities was inversely correlated with antioxidant defense. Our experiments showed that extra-mitochondrially or are attributed to the defective ROS levels found under these conditions may originate of electron transport [31], suggesting that the elevated production is inversely proportional to the rate optimal level, the rate of mitochondrial free radical production is at the subcellular enzymes including NADPH oxidases, xanthine oxidase [22, 23, 34]. Nevertheless, further studies should be taken to investigate the XST's specific mechanisms on inhibition of ROS generation.

Impaired ΔΨm, a sign of the early stage of cell apoptosis [35], occurred before nucleus apoptosis characteristics (chromatin condensed and DNA rupture). Once the mitochondrial transmembrane potential collapse, apoptosis procedure is irreversible [36]. In this experiment, we confirmed that the decreased ΔΨm was associated with the increase in the apoptosis cells (Figs. 5 and 6). XST, via elevation of ΔΨm and inhibition of mitochondrial ROS generation, exerted its anti-apoptotic effects in the hypoxia-reoxygenated HCM. Conclusively, the drug, via ensuring the integrity of the mitochondrial membrane, exerted its cardioprotective effects in the hypoxia-reoxygenated HCM.

Abbreviations
CHF: Chronic heart failure; ETC: Mitochondrial electron transport chain; HCM: Primary human cardiomyocyte; LVEF: Left ventricular ejection fraction; MPTP: Mitochondrial permeability transition pore; MTT: 3-[4,5-dimethylthiazol-2-yl]-diphenyl-tetrazolium bromide; NYHA: New York Heart Association; PBS: Phosphate-buffered saline; Pi: Inorganic phosphorus; ROS: Reactive oxygen species; SOD: Superoxide dismutase; XST: Xinshuitong Capsule; ΔΨm: Mitochondrial membrane potential

Acknowledgments
Thanks for the Molecular Biology Centre Laboratory of Fujian Academy of Integrative Medicine, Fujian Key Laboratory of Integrative Medicine on Geriatrics for the experiments.

Funding
This study is supported by the projects from Fujian Natural Science Foundation of China (No. 2013 J01334) Fujian Natural Science Foundation of Chinese-foreign cooperation Key Projects (No.201400012), Fujian Province Health and Family Planning Council (No.wzzy201313),Fujian University of TCM Supported Project (No.X2014137) and Fujian province health and family planning commission Foundation(No.2017-CX-39).

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Authors' contributions
CT Data collection and writing the paper, JZ and YW Drug quality inspection, JZH Cell experiments Cell viability assay, ΔΨm detection, mitochondrial respiratory chain complexes, total ATPase activity, mitochondrial ROS, apoptosis cells, WC Study design and experimental director. All authors have read and approved the final manuscript to submitted to this journal.

Ethics approval and consent to participate
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 14 March 2018 Accepted: 21 May 2018
Published online: 31 May 2018

References
1. Weiss JN, Korge P, Honda HM, Pinto P. Role of the mitochondrial permeability transition pore in myocardial disease. Circ Res. 2003;93:292–301.
2. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999;341:233–49.
3. Duchen MR, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin a sensitive mitochondrial pore in types are beyond the experimental reach of this study. A myocardial reperfusion injuryCardiovas Res. 1999;27:1790–4.
4. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp. 1995;61:1–31.
5. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357–63.
6. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500–8.
7. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H2O2 regulates cardiac myocyte phenotype via concentration dependent activation of distinct kinase pathways. J Mol Cell Cardiol. 2003;35:615–21.
8. Li JM, Gall NP, Greve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:77–84.
9. Li PC, Yang YC, Hwang GT, Kao LS, Lin CY. Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by Levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. PLoS One. 2014;9:e85909.
10. Tan CJ, Chen WL, Lin JM, Lin RH, Tan LF. Clinical research of Xinshuitong capsule on chronic heart failure in patients with diuretic resistance. Chin Arch Tradit Chin Med. 2011;29:837–9.
11. Tan CJ, Wu YB, Chen WL, Lin RH. Xinshuitong capsule ameliorates hypertrophy of cardiomyocytes via aquaporin pathway in the ischemia-reperfusion rat hearts. Int J Cardiol. 2011;152:554.
12. Xu L, Deng Y, Feng L, Li D, Chen X, Ma C, Liu X, Yin J, Yang M, Teng F, Wu W, Guan S, Jiang B, Guo D. Cardio-protective of salvianolic acid B through inhibition of apoptosis network. PLoS One. 2011;6:e24036.
13. Kavazis AN, Talbert EE, Smuder AJ, Hudson MB, Nelson WB, Powers SK. Mechanical ventilation induces diaphragmatic mitochondrial dysfunction and increased oxidant production. Free Radic Biol Med. 2009;46:684–50.
14. Alexander T. Assembly of the mitochondrial membrane system. I. Characterization of some enzymes of the inner membrane of yeast mitochondria. J Biol Chem. 1969;244:5020–6.
15. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem. 1925;66:375–400.
16. Lovhøj OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–75.
17. Almeida A, Moncada S, Bolaños JP. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol. 2004;6:45–51.

18. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997;416:15–8.

19. Aluri HS, Simpson DC, Allegood JC, Hu Y, Szczepanek K, Gronert S, Chen Q, Lesnffsky EJ. Electron flow into cytochrome c coupled with reactive oxygen species from the electron transport chain converts cytochrome c to a cardiolipin peroxidase: role during ischemia-reperfusion. Biochim Biophys Acta. 2014;1840:9–18.

20. Lesnffsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001;33:1065–89.

21. Chen Q, Moghaddas S, Hoppel CL, Lesnffsky EJ. Reversible blockade of electron transport during ischemia protects mitochondria and decreases myocardial injury following reperfusion. J Pharmacol Exp Ther. 2006;319:1405–12.

22. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem. 2002;80:780–9.

23. Skulachev VP. Uncoupling: new approaches to an old problem of bioenergetics. Biochim Biophys Acta. 1998;1363:100–24.

24. Brand MD, Buckingham JA, Esteves TC, Green K, Lambert AJ, Miwa S, Murphy MP, Pakay JL, Talbot DA, Echtay KS. Mitochondrial superoxide and aging: uncoupling-protein activity and superoxide production. Biochem Soc Symp. 2004;71:203–13.

25. Brookes PS. Mitochondrial H(+)-leak and ROS generation: an odd couple. Free Radic Biol Med. 2005;38:12–23.

26. Korge P, Ping P, Weiss JN. Reactive oxygen species production in energized cardiac mitochondria during hypoxia/reoxygenation: modulation by nitric oxide. Circ Res. 2008;103:873–80.

27. Petrosillo G, Ruggiero F, Di Venosa N, Paradies G. Decreased complex II activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin. FASEB J. 2003;17:714–6.

28. Zhang J, Plantadot SI. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest. 1992;90:193–9.

29. Rustin P, Chernien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994;228:35–51.

30. Cadenes E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000;29:222–30.

31. Vinogradov AD, Griiennikova VG. Generation of superoxide-radical by the NADH: ubiquinone oxidoreductase of heart mitochondria. Biochemistry. 2005;70:120–7.

32. Poderoso JJ, Carreras MC, Lisdero C, Robb N, Schöpfer F, Boever J. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys. 1996;328:85–92.

33. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.

34. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552:335–44.

35. Mathur A, Hong Y, Kemp BK. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res. 2000;46:126–38.

36. Suh DH, Kim MK, Kim HS. Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front Oncol. 2013;3:41.